Home | Careers | Contact Us About Us Therapeutic Focus Firdapse® Expanded Access Pipeline Business Development Investors News & Events Welcome Print Share Catalyst Pharmaceuticals Inc. (Catalyst Pharmaceuticals), is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. Catalyst's lead program, Firdapse®, was shown to be safe and effective in a 38 subject, pivotal phase III, global, multi-centered trial for the treatment of patients with Lambert - Eaton Myasthenic Syndrome (LEMS). LEMS is a rare autoimmune disorder with the primary symptoms of debilitating muscle weakness, where the immune system attacks the nerves that control the muscles. Firdapse® Expanded Access Program Catalyst Pharmaceuticals has announced the initiation of the Firdapse® Expanded Access Program which is a Phase IV open label study where patients who are diagnosed with LEMS and meet the inclusion and exclusion criteria can receive Firdapse® (at no cost) when a patient's physician feels Firdapse® can help improve his or her condition. 1-844-347-3277 (844-Firdapse) Read More Pipeline Catalyst Pharmaceuticals is also studying Firdapse® in other neurological orphan indications including Congenital Myasthenic Syndromes (CMS), and Downbeat Nystagmus. Other pipeline programs include CPP-115, which is under investigation in several neurological conditions such as post- traumatic stress disorders, Tourette’s disorders and infantile spasms. Read More Patient Advocacy Some of the numerous Advocacy Organizations which Catalyst is working with to help people with rare diseases include: Dysautonomia international www.dysautonomiainternational.org National Organization for Rare Disorders (NORD) www.rarediseases.org Global Genes www.globalgenes.org Muscular Dystrophy Association www.mda.org What’s New? August 17, 2015 — Catalyst Pharmaceuticals Appoints Paul J. Merrigan as Chief Commercial Officer... Read More August 10, 2015 — Catalyst Pharmaceuticals Announces Second Quarter 2015 Financial Results and Provides Corporate Update... Read More August 4, 2015 — Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Tuesday, August 11th, 2015... Read More July 22, 2015 — Catalyst Pharmaceuticals Initiates Rolling NDA Submission for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)... Read More June 30, 2015 — Catalyst Pharmaceuticals Appoints Dr. Gary Ingenito as Chief Medical Officer... Read More June 29, 2015 — Catalyst Pharmaceuticals Joins Russell 2000, 3000 and Global Indexes... Read More June 24, 2015 — Catalyst Pharmaceuticals Announces Encouraging Top-Line Results in Proof-of-Concept... Read More May 28, 2015 — Catalyst Pharmaceuticals Names Richard J. Daly Interim Chief Commercial Officer... Read More May 27, 2015 — Catalyst Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference... Read More May 11, 2015 — Catalyst Pharmaceuticals Announces First Quarter 2015 Financial Results and Provides Corporate Update.... Read More © 2021 CatalystPharma | Privacy Policy | Site Map | Webmail login Website by Axxiem